Metaplastic breast carcinoma with osteosarcomatous differentiation: a case report
-
By
-
Xiang Zhao
-
XiaoYu Sun
-
Jiaqi Liu
-
June 30, 2026
-
Clinical Scorecard: A Case Study of Metaplastic Breast Carcinoma Exhibiting Osteosarcomatous Differentiation
At a Glance
| Category | Detail |
|---|
| Condition | Metaplastic Breast Carcinoma (MBC) |
| Key Mechanisms | Aggressive malignancy with epithelial and non-glandular elements, including osteosarcomatous differentiation. |
| Target Population | Patients with metaplastic breast carcinoma, particularly those with osteosarcomatous differentiation. |
| Care Setting | Oncology and surgical settings for breast cancer treatment. |
Key Highlights
- MBC accounts for less than 0.2-1% of all breast cancers.
- Osteosarcomatous differentiation in MBC is extremely rare, representing 0.003%-0.12% of cases.
- Triple-negative phenotype is common in MBC, associated with poor prognosis.
- Multimodal treatment including surgery, chemotherapy, and immunotherapy may optimize outcomes.
- Postoperative BRCA1/2 testing was negative in the reported case.
Guideline-Based Recommendations
Diagnosis
- Core needle biopsy and imaging are essential for diagnosis of MBC.
Management
- Multimodal treatment including surgery, anthracycline-based chemotherapy, and immunotherapy is recommended.
Monitoring & Follow-up
- Regular imaging and clinical evaluation to assess treatment response and disease progression.
Risks
- MBC is associated with a higher mortality rate compared to other breast cancer subtypes.
Patient & Prescribing Data
65-year-old female with a history of invasive breast carcinoma.
Received TP regimen plus immunotherapy followed by AC chemotherapy and radiotherapy post-surgery.
Clinical Best Practices
- Consider multidisciplinary team consultations for treatment planning in complex cases of MBC.
- Utilize imaging and histopathological assessments for accurate diagnosis and treatment monitoring.
Related Resources & Content
